Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: Results from the randomized treatment withdrawal phase of a phase 3, randomized, controlled trial (ESTEEM 1)

Authors
Category Primary study
JournalJournal of the American Academy of Dermatology
Year 2014
This article has no abstract
Epistemonikos ID: 20bf204a85c30f7aa181dfc70aa77a07d0cb0264
First added on: Feb 05, 2025